GAD2 and encephalitis: Although anti-GAD65 encephalitis as a subclass of autoantibodies against intracellular antigens, differs in terms of pathogenesis and therapeutic focus from the AE discussed in this review, it remains possible that the therapeutic effects of basiliximab, which selectively inhibits activated cytotoxic T cells, may benefit patients with AE who have autoantibodies against cell membranes and ion channels, and maybe a potential therapeutic option.